Becton, Dickinson and Company

574 articles with Becton, Dickinson and Company

• New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

  11/13/2018

  Fully-automated BD Phoenix™ CPO Detect Test Receives U.S. FDA Clearance.

• BD to Present at the Stifel 2018 Healthcare Conference

  11/6/2018

  BD (Becton, Dickinson and Company) announced today that it will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018, at 11:45 AM ET.

• BD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance

  11/6/2018

  - As reported, full fiscal year revenues of $15.983 billion increased 32.2 percent.

• Thermo Fisher Scientific Completes Acquisition of Advanced Bioprocessing from BD

  10/26/2018

  Thermo Fisher Scientific Inc. today completed its previously announced acquisition of the Advanced Bioprocessing business from BD (Becton, Dickinson and Company – NYSE: BDX), a leading global medical technology company, for $477 million in cash, subject to post-closing adjustments. The business will be integrated into Thermo Fisher's Life Sciences Solutions Segment.

• BD To Invest $200 Million In Nebraska Operations Creating 300 More Jobs

  10/23/2018

  Brings Total Company Investment in Nebraska to $340 Million in Two Years

• BD Donates 20 Million Syringes to Support Polio Eradication

  10/17/2018

  Company Joins Effort Alongside Rotary and Leading Global Health Organizations to Expand Vaccinations in India

• BD Launches Molecular Test For Detecting Tuberculosis And Multi-Drug Resistant TB

  10/16/2018

  BD MAX™ MDR-TB Panel Obtains CE-IVD Status in Europe

• BD Breaks Ground at I.D.E.A. Tempe Campus

  10/3/2018

  Global Medical Technology Company To Be Anchor Tenant at New Campus

• BD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call

  10/3/2018

  BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2018 earnings conference call on Tuesday, November 6, 2018, at 8:00 a.m. (ET).

• Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD

  9/7/2018

  Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Company)

• BD Statement on Divestiture of Advanced Bioprocessing Business

  9/7/2018

  BD (Becton, Dickinson and Company) (NYSE: BDX) today issued the following statement regarding the sale of its Advanced Bioprocessing business to Thermo Fisher Scientific

• BD to Present at the Morgan Stanley 2018 Global Healthcare Conference

  8/30/2018

  BD (Becton, Dickinson and Company) announced today that it will present at the Morgan Stanley 2018 Global Healthcare Conference on Wednesday, September 12, 2018, at 11:40 a.m. ET.

• BD Awards $1 Million in Grants to Help Community Health Centers Drive Effective Medication Use Among Vulnerable Patients

  8/28/2018

  BD (Becton, Dickinson and Company), Direct Relief, and the National Association of Community Health Centers (NACHC) recently awarded five community health centers with a total of $1 million in grant funding, which will be used to expand programs that help vulnerable patients more effectively manage their medications.

• BD to Present at the Wells Fargo Securities 2018 Healthcare Conference

  8/22/2018

  BD (Becton, Dickinson and Company) announced today that it will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, September 5, 2018, at 3:00 PM ET.

• BD Elects Jeffrey Henderson to Board of Directors

  8/16/2018

  Henderson, 53, is the non-executive chairman of the board of Qualcomm, Inc. and serves on the board of directors at FibroGen, Inc. and Halozyme Therapeutics, Inc. as well as serving as an advisory director to Berkshire Partners LLC.

• BD Announces Results For 2018 Third Fiscal Quarter; Raises Fiscal 2018 Revenue Guidance

  8/2/2018

  As reported, revenues of $4.278 billion increased 41.0 percent.

• BD Appoints Simon Campion to Interventional Segment President

  8/1/2018

  BD (Becton, Dickinson and Company) appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4.

• BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis

  7/26/2018

  BD® AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune System

• BD Board Declares Dividends of $0.75 Per Common Share

  7/24/2018

  The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.75 per common share, payable on September 28, 2018 to holders of record on September 7, 2018.

• BD Shares Progress towards Achieving 2020 Sustainability Goals

  7/12/2018

  BD (Becton, Dickinson and Company)  issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company's 2020 Sustainability Goals.